Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
A total of 201 participants with chronic HCV GT4 infection were allocated into two groups.
One group participants were treated with SOF plus RBV (24 weeks). The second group was
treated with SOF plus SMV (12 weeks).